Last updated on November 2019

A Study Evaluating the Safety Pharmacokinetics (PK) and Preliminary Efficacy of ABBV-399 in Subjects With Advanced Solid Tumors


Brief description of study

This is a Phase 1/1b open-label study evaluating the safety, pharmacokinetics (PK), and preliminary efficacy of ABBV-399 as monotherapy and in combination with osimertinib, erlotinib, and nivolumab in subjects with advanced solid tumors likely to express c-Met. Enrollment is closed for the monotherapy arms, Arm A, and Arm D.

Clinical Study Identifier: NCT02099058

Find a site near you

Start Over